Bart L. Scott, MD

Articles by Bart L. Scott, MD

The Future of Chronic GvHD Treatment

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

August 11th 2023

Expert panelists share final thoughts concerning the future of chronic GvHD treatment, highlighting unmet needs, ongoing trials, and promising therapies.

Remote Patient Monitoring and Supportive Care Measures in Chronic GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

August 4th 2023

Addressing patient monitoring in chronic GvHD, including therapy adjustment indicators and frequency.

Data-Driven Treatment Selection for Patients with Chronic GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

August 4th 2023

Clinical pearls for community oncologists regarding treatment selection and sequencing in chronic GvHD patients.

A Comprehensive Look at Initial Treatment Options for Chronic GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 28th 2023

Exploring FDA-approved treatment options for patients with chronic GvHD, with a focus on trial data and adverse effects.

Establishing Treatment Objectives for Chronic GvHD: First-Line Strategies

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 28th 2023

Insights on treatment strategies and goals for initial chronic GvHD management, including treatment selection rationale and dosing.

Advancements and Promising Directions in Acute GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 21st 2023

Experienced clinicians discuss the future of acute GvHD treatment, focusing on gaps in patient care and potential therapy options.

Enhancing Patient Care in Acute GvHD: Supportive Measures

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 21st 2023

Supportive care measures for acute GvHD are explored, highlighting strategies to manage symptoms and improve patient well-being.

Treatment Options in Steroid-Refractory Acute GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 14th 2023

Treatment options for steroid refractory acute GvHD, including ruxolitinib efficacy and NCCN guideline adherence, take center stage in the discussion.

Optimal First-Line Treatment Approaches for Acute GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 14th 2023

Subject-matter experts delve into the diagnosis, risk assessment, and treatment selection process for acute GvHD, emphasizing differentiation of refractory disease.

Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

June 23rd 2023

Panelists Hannah Choe, MD, and Bart L Scott, MD share insights concerning prophylaxis in Graft-Versus-Host Disease, including key study data and current standards of care as well as discuss the potential role of biomarkers in GvHD.

Understanding Chronic and Acute Graft-Versus-Host Disease Presentation and Diagnosis

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

June 23rd 2023

Moderator Michael Bishop, MD introduces expert panelists and leads an overview of Graft-Versus-Host Disease, covering the differences between chronic and acute conditions, how GvHD is typically diagnosed, and GvHD risk assessment.

Dr. Scott on Connect MDS and AML: A Disease Registry

ByBart L. Scott, MD

April 30th 2015

Bart L. Scott, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses a new registry that will collect data from patients with MDS.